STOCK TITAN

Titan Pharmaceuticals Completes Debt Settlement With Molteni And Horizon & Acquisiton Of JT Pharma's Kappa Opioid Agonist Peptide, JT-09

Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Neutral)
Rhea-AI Summary

Titan Pharmaceuticals (NASDAQ:TTNP) has completed agreements to settle all debt obligations with Molteni & C and Horizon Credit LLC, and to acquire JT Pharmaceuticals' kappa opioid agonist peptide, JT-09. This acquisition aims to utilize Titan's ProNeura technology for chronic pruritus treatment. The completion of these transactions follows Titan's recent public offering concluded on October 30, 2020. Titan's Executive Chairman, Dr. Marc Rubin, stated that the debt settlement allows the company to fully leverage its intellectual property, enhancing its position for future development.

Positive
  • Completion of debt settlement enhances asset utilization and eliminates existing liens.
  • Acquisition of JT-09 positions Titan to expand its therapeutic pipeline for chronic pruritus.
Negative
  • None.

SOUTH SAN FRANCISCO, Calif., Nov. 2, 2020 /PRNewswire/ -- Titan Pharmaceuticals, Inc. (NASDAQ:TTNP) today announced the completion of its agreement to settle all of its debt obligations with Molteni & C. dei F.lli Alitti Società di Esercizio S.p.A ("Molteni") and Horizon Credit LLC II ("Horizon"), as well as its agreement to acquire JT Pharmaceuticals, Inc.'s  ("JT Pharma") kappa opioid agonist peptide, JT-09, for use in combination with Titan's ProNeura® long-term, continuous drug delivery technology, for the treatment of chronic pruritus.

The completion of both transactions had been subject to Titan's closing of its previously announced underwritten public offering, which occurred on October 30, 2020.

"As a result of the debt settlement with Molteni and Horizon, there are no liens remaining on any of Titan's assets, including all the ProNeura intellectual property," commented Titan's Executive Chairman, Dr. Marc Rubin. "With the net proceeds from our recent public offering, a significant reduction in operating expenses, and full ability to capitalize on our IP, we are well positioned to progress preclinical development of our ProNeura-based product candidate pipeline, including establishing proof of concept with JT-09 in the first half of 2021."

About Titan Pharmaceuticals

Titan Pharmaceuticals, Inc. (NASDAQ:TTNP), based in South San Francisco, CA, is a development stage company developing proprietary therapeutics with its ProNeura® long-term, continuous drug delivery technology.  The ProNeura technology has the potential to be used in developing products for treating a number of chronic conditions, where maintaining consistent, around-the-clock blood levels of medication may benefit the patient and improve medical outcomes. For more information about Titan, please visit www.titanpharm.com.

Forward-Looking Statements

This press release may contain "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such statements include, but are not limited to, any statements relating to our product development programs and any other statements that are not historical facts. Such statements involve risks and uncertainties that could negatively affect our business, operating results, financial condition and stock price. Factors that could cause actual results to differ materially from management's current expectations include those risks and uncertainties relating to our ability to raise capital, the winding down of U.S. commercial activities related to Probuphine, the regulatory approval process, the development, testing, production and marketing of our drug candidates, patent and intellectual property matters and strategic agreements and relationships. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations or any changes in events, conditions or circumstances on which any such statement is based, except as required by law.

CONTACT:

Stephen Kilmer
Investor Relations
(650) 989-2215
skilmer@titanpharm.com  

 

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/titan-pharmaceuticals-completes-debt-settlement-with-molteni-and-horizon--acquisiton-of-jt-pharmas-kappa-opioid-agonist-peptide-jt-09-301164603.html

SOURCE Titan Pharmaceuticals, Inc.

FAQ

What did Titan Pharmaceuticals announce on November 2, 2020?

Titan Pharmaceuticals announced the settlement of debt obligations and the acquisition of JT Pharmaceuticals' kappa opioid agonist peptide, JT-09.

How does the acquisition of JT-09 impact Titan Pharmaceuticals?

The acquisition allows Titan to leverage its ProNeura technology for developing treatments for chronic pruritus.

What is the significance of the debt settlement for Titan Pharmaceuticals?

The settlement removes all liens on Titan's assets, enabling better utilization of its intellectual property.

When was Titan's public offering completed that enabled these transactions?

Titan's underwritten public offering was completed on October 30, 2020.

TITAN PHARMACEUTICAL INC

NASDAQ:TTNP

TTNP Rankings

TTNP Latest News

TTNP Stock Data

3.59M
498.54k
45.47%
1.85%
1.1%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
United States of America
SAN FRANCISCO